Last €111.39 EUR
Change Today -0.363 / -0.32%
Volume 1.3K
VX1 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 1:03 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

vertex pharmaceuticals inc (VX1) Snapshot

Open
€111.99
Previous Close
€111.76
Day High
€114.27
Day Low
€111.39
52 Week High
01/23/15 - €114.27
52 Week Low
04/15/14 - €44.47
Market Cap
26.8B
Average Volume 10 Days
706.4
EPS TTM
--
Shares Outstanding
240.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERTEX PHARMACEUTICALS INC (VX1)

vertex pharmaceuticals inc (VX1) Related Businessweek News

View More BusinessWeek News

vertex pharmaceuticals inc (VX1) Details

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing other research and early-stage development programs. It markets KALYDECO to treat patients of six years of age and older with CF who have specific genetic mutations in their cystic fibrosis transmembrane conductance (CFTR) regulator gene in the United States, European Union, and Canada. The company also provides INCIVEK in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus infection, as well as markets telaprevir in other international markets. In addition, it is developing Ivacaftor in combination with CFTR corrector compounds, which has completed Phase III development program; and evaluating VX-661, a second investigational CFTR corrector, in combination with ivacaftor in Phase II clinical development. The company identifies and develops next-generation CFTR corrector compounds that evaluate in regimens combining ivacaftor with two CFTR corrector compounds. Further, it is involved in various other research and early-stage development programs, including programs in the areas of oncology, multiple sclerosis, and other serious and rare diseases. The company sells its products principally to major and selected regional wholesalers and specialty pharmacy providers in North America, as well as government-owned and supported customers in Europe. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

1,800 Employees
Last Reported Date: 02/11/14
Founded in 1989

vertex pharmaceuticals inc (VX1) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $583.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $553.8K
Special Counsel to the Chief Executive Office...
Total Annual Compensation: $465.0K
Compensation as of Fiscal Year 2013.

vertex pharmaceuticals inc (VX1) Key Developments

Vertex Pharmaceuticals Incorporated Announces Executive Changes

Vertex Pharmaceuticals Incorporated announced that effective January 20, 2015, Kenneth L. Horton transitioned from his role as the executive vice president and chief legal officer to a role as special counsel to chief executive officer. In his new role, Horton is no longer an executive officer of the company.

Vertex Pharmaceuticals Could Be The Target For Shire

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) could be the possible target for the Shire plc (LSE:SHP) next acquisition, Bloomberg said.

Vertex Pharmaceuticals Incorporated Provides Revenue Guidance for the Full Year of 2015

Vertex Pharmaceuticals Incorporated provided revenue guidance for the full year of 2015. In 2015, the company expects significant revenue growth, the expansion of KALYDECO. Again the company is giving guidance of $560 million to $580 million, a 20% to 25% increase over the $460 million that the company expects to record this year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VX1:GR €111.39 EUR -0.363

VX1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $69.81 USD +0.81
BioMarin Pharmaceutical Inc $97.69 USD +1.84
Jazz Pharmaceuticals PLC $175.56 USD -0.64
Regeneron Pharmaceuticals Inc $420.21 USD -0.60
Sigma-Aldrich Corp $137.69 USD 0.00
View Industry Companies
 

Industry Analysis

VX1

Industry Average

Valuation VX1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 37.7x
Price/Book 26.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 35.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERTEX PHARMACEUTICALS INC, please visit www.vrtx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.